Clinical trials: Hereditary Colorectal Cancer

Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

• Completed
• Age: 18 years and older
• Phase 1/2
• Results posted

A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.

Trial name

NCT03711058

Testing

Copanlisib, Nivolumab

Where

United States

Volunteers

48 people

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins